NCT
HOME CURRENT ARCHIVE COVID-19
HOME CURRENT ARCHIVE PUBLISH INSTRUCTIONS
FOR AUTHORS COVID-19 LOG IN / REGISTER HISTORY ABOUT US DIRECTORY CONTACT
Consensus Meeting of Management of Antibiotics on CAP (Community Acquired Pneumonia)

Sansores Martínez RH, Acuña Kaldman M, Castañeda Godoy, R., Castillo Sánchez JF, Chan Mérida, JF, Díaz Castañón, JJ, Dillmann Arroyo CM, Garza Salinas, S, Gómez Gómez A, Loustaunau Andrade MA, Mendoza Topete, LA, Palomar Lever A, Pedroza Granados J, Ponce de León Rosales S, Quiñones Falconi F, Rendón Pérez LA, Salazar Lezama MA, Sandoval Padilla RA, Sauceda Lumbreras R, Villegas Elizondo JF, Zavala Trujillo IG





2004, Number 2

2004; 63 (2)






ABSTRACT

The first mexican Consensus Meeting on CAP (Community Acquired Pneumonia) was held in Huatulco, Oaxaca, Mexico, on July 22–23, 2004. The event gathered the knowledge and personal participation of an important group of mexican specialists, with the aim of discussing the main topics regarding the management of this infectious pathology in the world and specifically in Mexico nowdays, in order to settle down guidelines and diverse criteria on the management of CAP in outpatients and in the hospital. Epidemiological, diagnostic, physiological, classification and treatment issues were discussed, with special focus on the behavior of causal pathogens and the resistance issues they show in Mexico. The spectrum of antibiotics used in the treatment of CAP was also a pivotal topic in the discussions, as long as it makes clear which antibiotic approaches are the most convenient in the way each modality of CAP is approached. Community Acquired Pneumonia (CAP) is a very heavy burden for the public health in the world and its morbidity and mortality rates are still unacceptable for current Medicine. From this point of view it is transcendentally important to be updated with the necessary data on susceptibility and antibiotic spectrum of the most common pathogens, as well as in the updated clinical management of CAP.

KEYWORDS

Pneumonia, epidemiology, antibioticotherapy..

REFERENCES

  1. British Thoracic Society. Guidelines for the management of community-acquired pneumonia in adults. Thorax 2001; 56 (Suppl): 1-64.

  2. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. AJRCCM 2001; 163: 1730-54.

  3. Soto H y cols. Neumonía adquirida en la comunidad en adultos. Elementos dóstico, evaluación de la gravedad. Guía de manejo y prevención. Enf Infec Microbiol 1999; 19(6): 301-16.

  4. Mandell LA, Bartlett JG, Dowell SF, File TM, et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. CID 2003; 37: 1405-33.

  5. Quiñones-Falconi F, Calva JJ, López-Vidal Y, Galicia-Velazco M, et al. Antimicrobial susceptibility patterns of Streptococcus pneumoniae in Mexico. Diag Microbiol Infect Dis 2004; 49: 53-8.

  6. Leroy O, Santre C, Beuscart C. A 5-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an ICU. Intensive Care Med 1995; 21: 24-31.

  7. Luna CM, et al. Community-acquired Pneumonia Etiology, Epidemiology, and Outcome at a Teaching Hospital in Argentina. CHEST 2000; 118: 1344-1354.

  8. Marston BJ, Plouffe JF, File TM, Hackman BA, Salstrom SJ, Lipman HB, Kolczak MS, Breiman RF. Incidence of Community-Acquired Pneumonia Requiring Hospitalization. Results of a Population-Based Active Surveillance Study in Ohio. Arch Intern Med 1997; 157: 1709-1718. 6v.

  9. Fang GC, Fine M, Orloff J. New and emergency etiologies for community acquired pneumonia, implications for therapy, a prospective multicenter study of 359 cases. Medicine 1990; 69: 307-316.

  10. Jacobs MR, Appelbaum PC, LASER Study Group. Susceptibility of 1100 Streptococcus pneumoniae strains isolated in 1997 from seven Latin American and Caribbean countries. Int J Antimicrob Agents 2000; 16: 17-24.

  11. Feikin DR, Schuchat A, Kolczad M, Barrett NL, Harrison L, Lefkowitz L, McGeer A, Farley M, Vugia DL, Lexau C, Stefonec KR, Patterson J, Jorgensen J. Mortality From Invasive Pneumococcal Pneumonia in the Era of Antibiotic Resistance, 1995-1997. Am J Public Health 2000; 90: 223-229.

  12. Asociación Mexicana de Infectología y Microbiología Clínica. Soto HJL, coordinador. Neumonía adquirida en la comunidad en adultos. Elementos de diagnóstico, evaluación de la gravedad. Guía de manejo y prevención. Enf Infec y Microbiol 1999; 19: 301-16.

  13. Finch R, Schürmann D, Collins O, et al. Economic assessment of the community-acquired pneumonia. Clin Chest Med 1999; 20: 599-605.

  14. Bryan CS. Acute community-acquired pneumonia: current diagnosis and treatment. JSC Med Assoc. 2001; 97(1): 19-26.

  15. Tice AD. Respiratory Infection. Community-Acquire Pneumonia: Recent Insights Into an Old Disease. www.medscape.com/viewarticle/458823_print.

  16. File TM, Garau J, Blasi F, Chidiac Ch, Klugman K, Lode H, Lonks JR, Mandell L, Ramíez J, Yu V. Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia. Chest 2004; 125: 1888-1901.

  17. Neumonía Adquirida en la Comunidad: Perspectivas Terapéuticas. Revista Panamericana de Infectología Vol. 6 Suppl 200.

  18. Moran GJ. New directions in antiinfective therapy for community-acquired pneumonia in the emergency department. Pharmacotherapy. 2001; 21(7 Pt 2): 95S-99S.

  19. Correa JC, Badaro R, Bumroongkit C, et al. Randomized, open-label, parallel group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization. Clin Ther 2003; 25: 1453-68.

  20. Sethi S. Gatifloxacin in community-acquired respiratory tract infection. Expert Opin Pharmacother. 2003; 4(10): 1847-55.

  21. Cunha BA. Empiric therapy of community-acquired pneumonia. Guidelines for the perplexed. Chest 2004; 125: 1913.

  22. Dorca J, Manresa F. Community-acquired pneumonia: initial management and empirical treatment. Eur Respir Mon 1997; 3: 36-55.

  23. Bartlett JG, Dowell SF, Mandell LA, File Jr TM, Musher DM and Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Clinical Infectious Diseases 2000; 31: 347-82.

  24. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH, and the Canadian community-acquired pneumonia working group. Canadian guidelines for the initial management of community-acquired pneumonia: An evidence-based update by the Canadian infectious diseases society and the Canadian thoracic society. Clinical Infectious Diseases 31: 383-421.

  25. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, Assessment of Severity, Antimicrobial therapy, and Prevention. Am J Respir Crit Care Med. 2001; Vol 163: 1730-1754.

  26. Grupo de Trabajo de la Asociación Latinoamericana del Tórax. Recomendaciones ALAT sobre la neumonía adquirida en la comunidad. Arch Bronconeumol 2001; 37: 340-348.

  27. Menendez R, Ferrando D, Valles JM, Vallterra J. Influence of deviation from guidelines on the outcome of community-acquired pneumonia. Chest 2002; 122(2): 612-7.

  28. Guidelines for the Management of Adults with Community-Acquired Pneumonia. American Thoracic Society. Am J Respir Crit Care Med 2001; Vol 163: 1730-1754.

  29. Fine MJ, Auble TE, Yealy DM, Hanusa BH, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336(4): 243-50.

  30. Castanheira M, Gales AC, Mendes RE, et al. Antimicrobial susceptibility of Streptococcus pneumoniae in Latin America: results from five years of the SENTRY antimicrobial surveillance program. Clin Microbiol Infect 2004; 10(7): 645-51.

  31. Treney Z, McPhee A, Papadakis. Maxime, Current Medical Diagnosis and treatment. Lange 39th Ed. New York 2000: 292-300.


2004, Number 2

2004; 63 (2)